Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > $30 up in one day coming

<< Previous

Bullboard Posts

Next >>

Comment by TeddyTenBagson Feb 11, 2021 8:58pm

257 Views

Post# 32548588

RE:RE:RE:RE:RE:$30 up in one day coming

Notice the no response? When you come with facts to prove them wrong, the pumpers always disappear.

Don't let anyone tell you listing on the Nasdaq will take us to the moon either. Literally does nothing to get new drugs and therapeutics to market faster than the current timelines. Opens them up to new investors, but doesn't mean the demand will be there. Compass Pathways is on the Nasdaq and has been floating around $1.5B-$2B market cap. Not like investors are dying to throw money at it right now.